Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...
CEO Rainer Blair said Danaher has the money and “leadership bandwidth” to strike further deals across any of its three business areas.
Medical Device Network on MSN
Masimo secures FDA approval for OIRD detection on wearable patient monitor
The newly cleared capability uses AI through the smartSET pulse oximetry sensor platform.
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of an abstract presented last Saturday at the Society for Technology in Anesthesia 2022 Annual Meeting, which ...
On 22 June 2026, Masimo, a Danaher company, received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory ...
These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...
Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced Dual SET® Pulse Oximetry for Root®, a highly versatile patient monitoring and connectivity hub. The first application of ...
The life sciences giant is transforming its diagnostics segment with its acquisition of Masimo Corporation, shifting from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results